Table 2:
Cohort demographics
| N (total 393) | % | |
|---|---|---|
|
| ||
| Mean age at diagnosis (SD) | 59.9 (12.4) | |
|
| ||
| Histology: | ||
| High grade serous | 281 | 71.5% |
| Low grade serous | 21 | 5.3% |
| Endometrioid | 28 | 7.1% |
| Clear cell | 21 | 5.3% |
| Adenocarcinoma | 19 | 4.8% |
| Carcinosarcoma | 14 | 3.6% |
| Other | 9 | 2.3% |
|
| ||
| Grade: | ||
| 1-2 | 35 | 8.9% |
| 3 | 355 | 90.3% |
| Unknown | 3 | 0.8% |
|
| ||
| Stage*: | ||
| I | 34 | 8.7% |
| II | 23 | 5.9% |
| III | 275 | 70.0% |
| IV | 55 | 14.0% |
| Unknown | 6 | 1.5% |
|
| ||
| Platinum Response†: | ||
| Sensitive | 219 | 68.2% |
| Resistant/refractory | 82 | 31.8% |
| Unknown | 92 | 55.7% |
|
| ||
| Cytoreduction‡: | ||
| Optimal | 274 | 69.7% |
| Suboptimal | 106 | 27.0% |
| Unknown | 13 | 3.3% |
|
| ||
| Neoadjuvant chemotherapy: | ||
| Yes | 48 | 12.2% |
| No | 332 | 84.5% |
| Unknown | 13 | 3.3% |
|
| ||
| BRCA1 or BRCA2§: | ||
| Wildtype | 302 | 76.8% |
| Germline mutation | 65 | 16.5% |
| Somatic mutation | 27 | 6.9% |
|
| ||
| Other HRD genes|: | ||
| Wildtype | 372 | 94.7% |
| Germline or somatic mutation | 21 | 5.3% |
|
| ||
| TP53: | ||
| Wildtype | 91 | 23.2% |
| Germline or somatic mutation | 302 | 76.8% |
*
Staged according to 1988 International Federation of Gynecology and Obstetrics (FIGO) ovarian cancer staging classification.
†
Platinum sensitive: no recurrence or progression within 6 months of platinum-containing primary adjuvant treatment.
‡
Optimal: less than 1 cm of residual disease.
§
One case with both somatic and germline mutation included in both categories.
|
HRD mutations (excluding BRCA1 or BRCA2) include ATM, BARD1, BRIP1, NBN, PALB2, RAD51C, and RAD51D.